LOAD MORE
You're viewed all 14 products
Impurities in Silodosin can affect its quality, safety, and efficacy. Depending on the type and level of impurities, they can impact the drug's pharmacological activity and stability and pose potential risks to patient health.
Impurities in Silodosin are detected and quantified using reversed-phase (RP) ultra-high-performance liquid chromatography (UHPLC). This method will allow for accurate identification and quantification of impurities.
Manufacturers can adopt several strategies to maintain control over impurity levels in Silodosin. They include using high-quality starting materials, optimizing synthesis and purification processes, implementing comprehensive quality control tests, and monitoring impurity levels at different stages of the manufacturing process.
Silodosin Impurities are stored at a controlled room temperature between 2-8°C or as indicated on the Certificate of Analysis (CoA).
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.